Publication: Results of cisplatin, adriamycin and etoposide chemotherapy in patients with recurrent and metastatic endometrial cancer
dc.contributor.buuauthor | Bilgin, Tufan | |
dc.contributor.buuauthor | Ozan, Hakan | |
dc.contributor.buuauthor | Kara, H. Filiz | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.department | Kadın Hastalıkları ve Doğum Ana Bilim Dalı | |
dc.contributor.scopusid | 7004103925 | |
dc.contributor.scopusid | 7003908072 | |
dc.contributor.scopusid | 36845105800 | |
dc.date.accessioned | 2023-08-08T11:24:48Z | |
dc.date.available | 2023-08-08T11:24:48Z | |
dc.date.issued | 2004 | |
dc.description.abstract | The efficacy of the combination treatment of cisplatin, adriamycin and etoposide were retrospectively evaluated in 26 recurrent or metastatic endometrial cancer patients. One hundred and twenty-three treatment courses were observed. Patients received 20 mg/m(2) cisplatin and 80 mg/m(2) etoposide by continuous IV infusion for three days and adriamycin 40 mg/m(2) IV the second day. Treatment courses were repeated every four weeks. Megestrol acetate, 160 mg/day, was added in six patients who had positive progesterone receptors. Ten (38.5%) women had complete and three (11.5%) patients had partial response with an overall response rate of 50%. Median follow-up was 24 months. Surviving patients were alive for four months and six years. Toxicity was mainly hematological and gastrointestinal ulcerations and stomatitis were also observed. | |
dc.identifier.citation | Bilgin, T. vd. (2004). “Results of cisplatin, adriamycin and etoposide chemotherapy in patients with recurrent and metastatic endometrial cancer”. European Journal of Gynaecological Oncology, 25(3), 379-380. | |
dc.identifier.endpage | 380 | |
dc.identifier.issn | 0392-2936 | |
dc.identifier.issue | 3 | |
dc.identifier.pubmed | 15171324 | |
dc.identifier.scopus | 2-s2.0-2342525248 | |
dc.identifier.startpage | 379 | |
dc.identifier.uri | https://www.imrpress.com/journal/ejgo/25/3/pii/2004187 | |
dc.identifier.uri | http://hdl.handle.net/11452/33403 | |
dc.identifier.volume | 25 | |
dc.identifier.wos | 000221429600025 | |
dc.indexed.wos | SCIE | |
dc.language.iso | en | |
dc.publisher | MRE Press | |
dc.relation.journal | European Journal of Gynaecological Oncology | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Oncology | |
dc.subject | Obstetrics and gynecology | |
dc.subject | Endometrial cancer | |
dc.subject | Chemotherapy | |
dc.subject | Cisplatin | |
dc.subject | Adriamycin | |
dc.subject | Etoposide | |
dc.subject | Medroxyprogesterone acetate | |
dc.subject | Adenocarcinoma | |
dc.subject | Cyclophosphamide | |
dc.subject | 5-Fluorouracil | |
dc.subject | Doxorubicin | |
dc.subject | Paclitaxel | |
dc.subject | Epirubicin | |
dc.subject | Carcinoma | |
dc.subject | Regimen | |
dc.subject.emtree | Adult | |
dc.subject.emtree | Aged | |
dc.subject.emtree | Anemia | |
dc.subject.emtree | Article | |
dc.subject.emtree | Blood toxicity | |
dc.subject.emtree | Cancer combination chemotherapy | |
dc.subject.emtree | Cancer localization | |
dc.subject.emtree | Clinical article | |
dc.subject.emtree | Clinical trial | |
dc.subject.emtree | Controlled clinical trial | |
dc.subject.emtree | Controlled study | |
dc.subject.emtree | Diarrhea | |
dc.subject.emtree | Digestive system ulcer | |
dc.subject.emtree | Drug efficacy | |
dc.subject.emtree | Endometrium cancer | |
dc.subject.emtree | Female | |
dc.subject.emtree | Fever | |
dc.subject.emtree | Gastrointestinal hemorrhage | |
dc.subject.emtree | Human | |
dc.subject.emtree | Melena | |
dc.subject.emtree | Metastasis | |
dc.subject.emtree | Neutropenia | |
dc.subject.emtree | Recurrent cancer | |
dc.subject.emtree | Stomatitis | |
dc.subject.emtree | Survival time | |
dc.subject.emtree | Thrombocytopenia | |
dc.subject.emtree | Cisplatin | |
dc.subject.emtree | Doxorubicin | |
dc.subject.emtree | Etoposide | |
dc.subject.emtree | Megestrol acetate | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Antineoplastic combined chemotherapy protocols | |
dc.subject.mesh | Cisplatin | |
dc.subject.mesh | Doxorubicin | |
dc.subject.mesh | Endometrial neoplasms | |
dc.subject.mesh | Etoposide | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Medical records | |
dc.subject.mesh | Middle aged | |
dc.subject.mesh | Neoplasm metastasis | |
dc.subject.mesh | Neoplasm recurrence, local | |
dc.subject.mesh | Retrospective studies | |
dc.subject.mesh | Survival analysis | |
dc.subject.mesh | Treatment outcome | |
dc.subject.mesh | Turkey | |
dc.subject.scopus | Sentinel Lymph Node; Endometrial Neoplasms; Cancer Staging | |
dc.subject.wos | Oncology | |
dc.subject.wos | Obstetrics and gynecology | |
dc.title | Results of cisplatin, adriamycin and etoposide chemotherapy in patients with recurrent and metastatic endometrial cancer | |
dc.type | Article | |
dc.wos.quartile | Q4 | |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültesi/Kadın Hastalıkları ve Doğum Ana Bilim Dalı | |
local.indexed.at | PubMed | |
local.indexed.at | WOS |
Files
License bundle
1 - 1 of 1
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: